All the news articles and press releases in one place.


Date / Time Source Company % Chg Sector Market Cap Announcement
24Jan20 07:00 RNS-R Shield Therapeutics 0.61% Health £192.8m Investor presentations
14Jan20 07:15 EQS Shield Therapeutics 0.61% Health £192.8m Hardman & Co Research: Shield Therapeutics (STX): Taking on China
08Jan20 07:00 RNS Shield Therapeutics 0.61% Health £192.8m China licence agreement for Feraccru/Accrufer
12Dec19 17:30 RNS Eland Oil & Gas 2.80% Various Various Eland Oil & Gas
29Nov19 15:31 RNS Shield Therapeutics 0.61% Health £192.8m Holding(s) in Company
25Nov19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m QCA Corporate Governance Code
30Oct19 07:30 EQS Shield Therapeutics 0.61% Health £192.8m Hardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients
22Oct19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Positive results presented at UEG Week 2019
26Sep19 07:00 RNS-R Shield Therapeutics 0.61% Health £192.8m Investor Presentation
02Sep19 09:14 EQS Shield Therapeutics 0.61% Health £192.8m Hardman & Co Research: Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
29Aug19 07:00 RNS-R Shield Therapeutics 0.61% Health £192.8m Investor presentations
15Aug19 10:17 RNS Shield Therapeutics 0.61% Health £192.8m Director/PDMR Shareholding
07Aug19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Half-year Report
05Aug19 11:22 EQS Shield Therapeutics 0.61% Health £192.8m Hardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity
31Jul19 13:21 RNS Shield Therapeutics 0.61% Health £192.8m Notice of Results
26Jul19 14:05 RNS Shield Therapeutics 0.61% Health £192.8m Second Price Monitoring Extn
26Jul19 14:00 RNS Shield Therapeutics 0.61% Health £192.8m Price Monitoring Extension
26Jul19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m FDA approves Feraccru® with a broad label
02Jul19 12:00 RNS Shield Therapeutics 0.61% Health £192.8m Additional Listing
13Jun19 14:16 RNS Shield Therapeutics 0.61% Health £192.8m Result of AGM
03Jun19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Update on Legal Proceedings
13May19 12:00 EQS Shield Therapeutics 0.61% Health £192.8m Hardman & Co Research: Shield Therapeutics (STX): All in the execution
08May19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Appointment of Joint Broker
02May19 07:00 RNS-R Shield Therapeutics 0.61% Health £192.8m Investor presentation
01May19 11:58 RNS Shield Therapeutics 0.61% Health £192.8m Additional Listing
30Apr19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m 2018 Annual Report and 2019 AGM Notice
26Apr19 18:05 RNS Shield Therapeutics 0.61% Health £192.8m PDMR Acquisition of Shares
24Apr19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Major extension to approval in Switzerland
17Apr19 17:06 RNS Shield Therapeutics 0.61% Health £192.8m Grant of share options
17Apr19 17:01 RNS Shield Therapeutics 0.61% Health £192.8m PDMR Acquisition of Shares and Additional Listing
17Apr19 16:56 RNS Shield Therapeutics 0.61% Health £192.8m PDMR Acquisition of Shares
11Apr19 16:40 RNS Shield Therapeutics 0.61% Health £192.8m Holding(s) in Company
08Apr19 15:42 RNS Shield Therapeutics 0.61% Health £192.8m Additional Listing
03Apr19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Final Results
01Apr19 17:44 RNS Shield Therapeutics 0.61% Health £192.8m Additional Listing
01Apr19 12:00 RNS Shield Therapeutics 0.61% Health £192.8m Change of Adviser
27Mar19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Notice of Results
14Mar19 15:31 RNS Shield Therapeutics 0.61% Health £192.8m Positive decision on Feraccru®'s process patent
04Mar19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Positive results for Feraccru® in AEGIS-H2H study
29Jan19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Positive results of AEGIS-CKD study
28Jan19 07:15 EQS Shield Therapeutics 0.61% Health £192.8m Hardman & Co Research: Shield Therapeutics (STX): Cast-iron investment
24Jan19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Business and trading update
23Jan19 10:19 RNS-R Shield Therapeutics 0.61% Health £192.8m Investor presentations
22Jan19 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Appointment of Chairman
13Dec18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m US New Drug Application PDUFA date for Feraccru
05Dec18 10:04 RNS-R Shield Therapeutics 0.61% Health £192.8m UK launch of Feraccru® by Norgine
03Dec18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m New Drug Application for Feraccru®
09Nov18 15:46 RNS Shield Therapeutics 0.61% Health £192.8m Holding(s) in Company
08Nov18 18:21 RNS Shield Therapeutics 0.61% Health £192.8m Holding(s) in Company
01Oct18 13:54 RNS Shield Therapeutics 0.61% Health £192.8m Notification Of Major Holdings
01Oct18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Submission of an NDA for Feraccru® with the FDA
24Sep18 13:06 RNS Shield Therapeutics 0.61% Health £192.8m Director/PDMR Shareholding
24Sep18 13:02 RNS Shield Therapeutics 0.61% Health £192.8m Holding(s) in Company
19Sep18 07:14 RNS Shield Therapeutics 0.61% Health £192.8m Licence for the commercialisation of Feraccru
19Sep18 07:12 RNS Shield Therapeutics 0.61% Health £192.8m Interim Results
13Sep18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m AEGIS-H2H Completion of Recruitment
26Jul18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Appointment of Non-Executive Director
23Jul18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Business Update
09Jul18 16:27 RNS Shield Therapeutics 0.61% Health £192.8m Holdings in Company
09Jul18 16:26 RNS Shield Therapeutics 0.61% Health £192.8m Holdings in Company
28Jun18 11:56 RNS Shield Therapeutics 0.61% Health £192.8m Result of AGM
14Jun18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Positive top-line results from AEGIS-PAED PK study
05Jun18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Directorate Change
05Jun18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m 2017 Annual Report and 2018 AGM Notice
15May18 18:21 RNS Shield Therapeutics 0.61% Health £192.8m Grant of share options
04May18 09:20 RNS Shield Therapeutics 0.61% Health £192.8m Holding(s) in Company
03May18 17:26 RNS Shield Therapeutics 0.61% Health £192.8m Holding(s) in Company
02May18 11:00 RNS Shield Therapeutics 0.61% Health £192.8m Price Monitoring Extension
11Apr18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Preliminary Results for the Year Ended 31 Dec 17
06Apr18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Appointment of Non-Executive Director
06Apr18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Results of Pre-Submission Meeting with FDA
27Mar18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Broadening of Feraccru indication
16Mar18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Update on the AEGIS-CKD study
23Feb18 13:56 RNS Shield Therapeutics 0.61% Health £192.8m Receives CHMP positive opinion on Feraccru®
22Feb18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Business and Trading Update
05Feb18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Top-line results from Feraccru Phase III study
29Jan18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Notice of Results
25Jan18 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Grant of share options
10Oct17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Completion of patient enrolment in Phase 3 study
05Oct17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m PDMR Acquisition of Shares
20Sep17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Interim Report
14Sep17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Board Change
06Sep17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m US Composition of Matter Patent Allowed
31Aug17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Shield to Present at Baird Healthcare Conference
15Aug17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Notice of Results
11Jul17 14:59 RNS Shield Therapeutics 0.61% Health £192.8m Grant of Share Options
10Jul17 16:16 RNS Aviva Plc 1.25% Various Various Holding(s) in Company
06Jul17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Feraccru licence agreement for Switzerland
05Jul17 12:38 RNS Shield Therapeutics 0.61% Health £192.8m Holding(s) in Company
03Jul17 12:34 RNS Shield Therapeutics 0.61% Health £192.8m Warrant Exercise and Expiry
28Jun17 10:37 RNS Shield Therapeutics 0.61% Health £192.8m Holding(s) in Company
28Jun17 08:00 RNS Shield Therapeutics 0.61% Health £192.8m Admission of New Ordinary Shares
15Jun17 13:59 RNS Shield Therapeutics 0.61% Health £192.8m Results of Fundraise
15Jun17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Proposed Fundraise
13Jun17 14:40 RNS Shield Therapeutics 0.61% Health £192.8m Result of AGM
26May17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Appointment of Joint Broker
28Apr17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Annual Report, Accounts and AGM Notification
04Apr17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Appointment of Chief Financial Officer
04Apr17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Preliminary Results for the Year Ended 31 Dec 2016
13Mar17 07:00 RNS Shield Therapeutics 0.61% Health £192.8m Notice of Results
Date / Time Source Company % Chg
24Jan20 07:00 RNS-R Shield Therapeutics 0.61%
Investor presentations
14Jan20 07:15 EQS Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): Taking on China
08Jan20 07:00 RNS Shield Therapeutics 0.61%
China licence agreement for Feraccru/Accrufer
12Dec19 17:30 RNS Eland Oil & Gas 2.80%
Eland Oil & Gas
29Nov19 15:31 RNS Shield Therapeutics 0.61%
Holding(s) in Company
25Nov19 07:00 RNS Shield Therapeutics 0.61%
QCA Corporate Governance Code
30Oct19 07:30 EQS Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients
22Oct19 07:00 RNS Shield Therapeutics 0.61%
Positive results presented at UEG Week 2019
26Sep19 07:00 RNS-R Shield Therapeutics 0.61%
Investor Presentation
02Sep19 09:14 EQS Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
29Aug19 07:00 RNS-R Shield Therapeutics 0.61%
Investor presentations
15Aug19 10:17 RNS Shield Therapeutics 0.61%
Director/PDMR Shareholding
07Aug19 07:00 RNS Shield Therapeutics 0.61%
Half-year Report
05Aug19 11:22 EQS Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity
31Jul19 13:21 RNS Shield Therapeutics 0.61%
Notice of Results
26Jul19 14:05 RNS Shield Therapeutics 0.61%
Second Price Monitoring Extn
26Jul19 14:00 RNS Shield Therapeutics 0.61%
Price Monitoring Extension
26Jul19 07:00 RNS Shield Therapeutics 0.61%
FDA approves Feraccru® with a broad label
02Jul19 12:00 RNS Shield Therapeutics 0.61%
Additional Listing
13Jun19 14:16 RNS Shield Therapeutics 0.61%
Result of AGM
03Jun19 07:00 RNS Shield Therapeutics 0.61%
Update on Legal Proceedings
13May19 12:00 EQS Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): All in the execution
08May19 07:00 RNS Shield Therapeutics 0.61%
Appointment of Joint Broker
02May19 07:00 RNS-R Shield Therapeutics 0.61%
Investor presentation
01May19 11:58 RNS Shield Therapeutics 0.61%
Additional Listing
30Apr19 07:00 RNS Shield Therapeutics 0.61%
2018 Annual Report and 2019 AGM Notice
26Apr19 18:05 RNS Shield Therapeutics 0.61%
PDMR Acquisition of Shares
24Apr19 07:00 RNS Shield Therapeutics 0.61%
Major extension to approval in Switzerland
17Apr19 17:06 RNS Shield Therapeutics 0.61%
Grant of share options
17Apr19 17:01 RNS Shield Therapeutics 0.61%
PDMR Acquisition of Shares and Additional Listing
17Apr19 16:56 RNS Shield Therapeutics 0.61%
PDMR Acquisition of Shares
11Apr19 16:40 RNS Shield Therapeutics 0.61%
Holding(s) in Company
08Apr19 15:42 RNS Shield Therapeutics 0.61%
Additional Listing
03Apr19 07:00 RNS Shield Therapeutics 0.61%
Final Results
01Apr19 17:44 RNS Shield Therapeutics 0.61%
Additional Listing
01Apr19 12:00 RNS Shield Therapeutics 0.61%
Change of Adviser
27Mar19 07:00 RNS Shield Therapeutics 0.61%
Notice of Results
14Mar19 15:31 RNS Shield Therapeutics 0.61%
Positive decision on Feraccru®'s process patent
04Mar19 07:00 RNS Shield Therapeutics 0.61%
Positive results for Feraccru® in AEGIS-H2H study
29Jan19 07:00 RNS Shield Therapeutics 0.61%
Positive results of AEGIS-CKD study
28Jan19 07:15 EQS Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): Cast-iron investment
24Jan19 07:00 RNS Shield Therapeutics 0.61%
Business and trading update
23Jan19 10:19 RNS-R Shield Therapeutics 0.61%
Investor presentations
22Jan19 07:00 RNS Shield Therapeutics 0.61%
Appointment of Chairman
13Dec18 07:00 RNS Shield Therapeutics 0.61%
US New Drug Application PDUFA date for Feraccru
05Dec18 10:04 RNS-R Shield Therapeutics 0.61%
UK launch of Feraccru® by Norgine
03Dec18 07:00 RNS Shield Therapeutics 0.61%
New Drug Application for Feraccru®
09Nov18 15:46 RNS Shield Therapeutics 0.61%
Holding(s) in Company
08Nov18 18:21 RNS Shield Therapeutics 0.61%
Holding(s) in Company
01Oct18 13:54 RNS Shield Therapeutics 0.61%
Notification Of Major Holdings
01Oct18 07:00 RNS Shield Therapeutics 0.61%
Submission of an NDA for Feraccru® with the FDA
24Sep18 13:06 RNS Shield Therapeutics 0.61%
Director/PDMR Shareholding
24Sep18 13:02 RNS Shield Therapeutics 0.61%
Holding(s) in Company
19Sep18 07:14 RNS Shield Therapeutics 0.61%
Licence for the commercialisation of Feraccru
19Sep18 07:12 RNS Shield Therapeutics 0.61%
Interim Results
13Sep18 07:00 RNS Shield Therapeutics 0.61%
AEGIS-H2H Completion of Recruitment
26Jul18 07:00 RNS Shield Therapeutics 0.61%
Appointment of Non-Executive Director
23Jul18 07:00 RNS Shield Therapeutics 0.61%
Business Update
09Jul18 16:27 RNS Shield Therapeutics 0.61%
Holdings in Company
09Jul18 16:26 RNS Shield Therapeutics 0.61%
Holdings in Company
28Jun18 11:56 RNS Shield Therapeutics 0.61%
Result of AGM
14Jun18 07:00 RNS Shield Therapeutics 0.61%
Positive top-line results from AEGIS-PAED PK study
05Jun18 07:00 RNS Shield Therapeutics 0.61%
Directorate Change
05Jun18 07:00 RNS Shield Therapeutics 0.61%
2017 Annual Report and 2018 AGM Notice
15May18 18:21 RNS Shield Therapeutics 0.61%
Grant of share options
04May18 09:20 RNS Shield Therapeutics 0.61%
Holding(s) in Company
03May18 17:26 RNS Shield Therapeutics 0.61%
Holding(s) in Company
02May18 11:00 RNS Shield Therapeutics 0.61%
Price Monitoring Extension
11Apr18 07:00 RNS Shield Therapeutics 0.61%
Preliminary Results for the Year Ended 31 Dec 17
06Apr18 07:00 RNS Shield Therapeutics 0.61%
Appointment of Non-Executive Director
06Apr18 07:00 RNS Shield Therapeutics 0.61%
Results of Pre-Submission Meeting with FDA
27Mar18 07:00 RNS Shield Therapeutics 0.61%
Broadening of Feraccru indication
16Mar18 07:00 RNS Shield Therapeutics 0.61%
Update on the AEGIS-CKD study
23Feb18 13:56 RNS Shield Therapeutics 0.61%
Receives CHMP positive opinion on Feraccru®
22Feb18 07:00 RNS Shield Therapeutics 0.61%
Business and Trading Update
05Feb18 07:00 RNS Shield Therapeutics 0.61%
Top-line results from Feraccru Phase III study
29Jan18 07:00 RNS Shield Therapeutics 0.61%
Notice of Results
25Jan18 07:00 RNS Shield Therapeutics 0.61%
Grant of share options
10Oct17 07:00 RNS Shield Therapeutics 0.61%
Completion of patient enrolment in Phase 3 study
05Oct17 07:00 RNS Shield Therapeutics 0.61%
PDMR Acquisition of Shares
20Sep17 07:00 RNS Shield Therapeutics 0.61%
Interim Report
14Sep17 07:00 RNS Shield Therapeutics 0.61%
Board Change
06Sep17 07:00 RNS Shield Therapeutics 0.61%
US Composition of Matter Patent Allowed
31Aug17 07:00 RNS Shield Therapeutics 0.61%
Shield to Present at Baird Healthcare Conference
15Aug17 07:00 RNS Shield Therapeutics 0.61%
Notice of Results
11Jul17 14:59 RNS Shield Therapeutics 0.61%
Grant of Share Options
10Jul17 16:16 RNS Aviva Plc 1.25%
Holding(s) in Company
06Jul17 07:00 RNS Shield Therapeutics 0.61%
Feraccru licence agreement for Switzerland
05Jul17 12:38 RNS Shield Therapeutics 0.61%
Holding(s) in Company
03Jul17 12:34 RNS Shield Therapeutics 0.61%
Warrant Exercise and Expiry
28Jun17 10:37 RNS Shield Therapeutics 0.61%
Holding(s) in Company
28Jun17 08:00 RNS Shield Therapeutics 0.61%
Admission of New Ordinary Shares
15Jun17 13:59 RNS Shield Therapeutics 0.61%
Results of Fundraise
15Jun17 07:00 RNS Shield Therapeutics 0.61%
Proposed Fundraise
13Jun17 14:40 RNS Shield Therapeutics 0.61%
Result of AGM
26May17 07:00 RNS Shield Therapeutics 0.61%
Appointment of Joint Broker
28Apr17 07:00 RNS Shield Therapeutics 0.61%
Annual Report, Accounts and AGM Notification
04Apr17 07:00 RNS Shield Therapeutics 0.61%
Appointment of Chief Financial Officer
04Apr17 07:00 RNS Shield Therapeutics 0.61%
Preliminary Results for the Year Ended 31 Dec 2016
13Mar17 07:00 RNS Shield Therapeutics 0.61%
Notice of Results
Date / Time Company % Chg
24Jan20 07:00 Shield Therapeutics 0.61%
Investor presentations
14Jan20 07:15 Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): Taking on China
08Jan20 07:00 Shield Therapeutics 0.61%
China licence agreement for Feraccru/Accrufer
12Dec19 17:30 ELA LSE,STX LSE,WHR LSE 2.80%
Eland Oil & Gas
29Nov19 15:31 Shield Therapeutics 0.61%
Holding(s) in Company
25Nov19 07:00 Shield Therapeutics 0.61%
QCA Corporate Governance Code
30Oct19 07:30 Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients
22Oct19 07:00 Shield Therapeutics 0.61%
Positive results presented at UEG Week 2019
26Sep19 07:00 Shield Therapeutics 0.61%
Investor Presentation
02Sep19 09:14 Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
29Aug19 07:00 Shield Therapeutics 0.61%
Investor presentations
15Aug19 10:17 Shield Therapeutics 0.61%
Director/PDMR Shareholding
07Aug19 07:00 Shield Therapeutics 0.61%
Half-year Report
05Aug19 11:22 Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity
31Jul19 13:21 Shield Therapeutics 0.61%
Notice of Results
26Jul19 14:05 Shield Therapeutics 0.61%
Second Price Monitoring Extn
26Jul19 14:00 Shield Therapeutics 0.61%
Price Monitoring Extension
26Jul19 07:00 Shield Therapeutics 0.61%
FDA approves Feraccru® with a broad label
02Jul19 12:00 Shield Therapeutics 0.61%
Additional Listing
13Jun19 14:16 Shield Therapeutics 0.61%
Result of AGM
03Jun19 07:00 Shield Therapeutics 0.61%
Update on Legal Proceedings
13May19 12:00 Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): All in the execution
08May19 07:00 Shield Therapeutics 0.61%
Appointment of Joint Broker
02May19 07:00 Shield Therapeutics 0.61%
Investor presentation
01May19 11:58 Shield Therapeutics 0.61%
Additional Listing
30Apr19 07:00 Shield Therapeutics 0.61%
2018 Annual Report and 2019 AGM Notice
26Apr19 18:05 Shield Therapeutics 0.61%
PDMR Acquisition of Shares
24Apr19 07:00 Shield Therapeutics 0.61%
Major extension to approval in Switzerland
17Apr19 17:06 Shield Therapeutics 0.61%
Grant of share options
17Apr19 17:01 Shield Therapeutics 0.61%
PDMR Acquisition of Shares and Additional Listing
17Apr19 16:56 Shield Therapeutics 0.61%
PDMR Acquisition of Shares
11Apr19 16:40 Shield Therapeutics 0.61%
Holding(s) in Company
08Apr19 15:42 Shield Therapeutics 0.61%
Additional Listing
03Apr19 07:00 Shield Therapeutics 0.61%
Final Results
01Apr19 17:44 Shield Therapeutics 0.61%
Additional Listing
01Apr19 12:00 Shield Therapeutics 0.61%
Change of Adviser
27Mar19 07:00 Shield Therapeutics 0.61%
Notice of Results
14Mar19 15:31 Shield Therapeutics 0.61%
Positive decision on Feraccru®'s process patent
04Mar19 07:00 Shield Therapeutics 0.61%
Positive results for Feraccru® in AEGIS-H2H study
29Jan19 07:00 Shield Therapeutics 0.61%
Positive results of AEGIS-CKD study
28Jan19 07:15 Shield Therapeutics 0.61%
Hardman & Co Research: Shield Therapeutics (STX): Cast-iron investment
24Jan19 07:00 Shield Therapeutics 0.61%
Business and trading update
23Jan19 10:19 Shield Therapeutics 0.61%
Investor presentations
22Jan19 07:00 Shield Therapeutics 0.61%
Appointment of Chairman
13Dec18 07:00 Shield Therapeutics 0.61%
US New Drug Application PDUFA date for Feraccru
05Dec18 10:04 Shield Therapeutics 0.61%
UK launch of Feraccru® by Norgine
03Dec18 07:00 Shield Therapeutics 0.61%
New Drug Application for Feraccru®
09Nov18 15:46 Shield Therapeutics 0.61%
Holding(s) in Company
08Nov18 18:21 Shield Therapeutics 0.61%
Holding(s) in Company
01Oct18 13:54 Shield Therapeutics 0.61%
Notification Of Major Holdings
01Oct18 07:00 Shield Therapeutics 0.61%
Submission of an NDA for Feraccru® with the FDA
24Sep18 13:06 Shield Therapeutics 0.61%
Director/PDMR Shareholding
24Sep18 13:02 Shield Therapeutics 0.61%
Holding(s) in Company
19Sep18 07:14 Shield Therapeutics 0.61%
Licence for the commercialisation of Feraccru
19Sep18 07:12 Shield Therapeutics 0.61%
Interim Results
13Sep18 07:00 Shield Therapeutics 0.61%
AEGIS-H2H Completion of Recruitment
26Jul18 07:00 Shield Therapeutics 0.61%
Appointment of Non-Executive Director
23Jul18 07:00 Shield Therapeutics 0.61%
Business Update
09Jul18 16:27 Shield Therapeutics 0.61%
Holdings in Company
09Jul18 16:26 Shield Therapeutics 0.61%
Holdings in Company
28Jun18 11:56 Shield Therapeutics 0.61%
Result of AGM
14Jun18 07:00 Shield Therapeutics 0.61%
Positive top-line results from AEGIS-PAED PK study
05Jun18 07:00 Shield Therapeutics 0.61%
Directorate Change
05Jun18 07:00 Shield Therapeutics 0.61%
2017 Annual Report and 2018 AGM Notice
15May18 18:21 Shield Therapeutics 0.61%
Grant of share options
04May18 09:20 Shield Therapeutics 0.61%
Holding(s) in Company
03May18 17:26 Shield Therapeutics 0.61%
Holding(s) in Company
02May18 11:00 Shield Therapeutics 0.61%
Price Monitoring Extension
11Apr18 07:00 Shield Therapeutics 0.61%
Preliminary Results for the Year Ended 31 Dec 17
06Apr18 07:00 Shield Therapeutics 0.61%
Appointment of Non-Executive Director
06Apr18 07:00 Shield Therapeutics 0.61%
Results of Pre-Submission Meeting with FDA
27Mar18 07:00 Shield Therapeutics 0.61%
Broadening of Feraccru indication
16Mar18 07:00 Shield Therapeutics 0.61%
Update on the AEGIS-CKD study
23Feb18 13:56 Shield Therapeutics 0.61%
Receives CHMP positive opinion on Feraccru®
22Feb18 07:00 Shield Therapeutics 0.61%
Business and Trading Update
05Feb18 07:00 Shield Therapeutics 0.61%
Top-line results from Feraccru Phase III study
29Jan18 07:00 Shield Therapeutics 0.61%
Notice of Results
25Jan18 07:00 Shield Therapeutics 0.61%
Grant of share options
10Oct17 07:00 Shield Therapeutics 0.61%
Completion of patient enrolment in Phase 3 study
05Oct17 07:00 Shield Therapeutics 0.61%
PDMR Acquisition of Shares
20Sep17 07:00 Shield Therapeutics 0.61%
Interim Report
14Sep17 07:00 Shield Therapeutics 0.61%
Board Change
06Sep17 07:00 Shield Therapeutics 0.61%
US Composition of Matter Patent Allowed
31Aug17 07:00 Shield Therapeutics 0.61%
Shield to Present at Baird Healthcare Conference
15Aug17 07:00 Shield Therapeutics 0.61%
Notice of Results
11Jul17 14:59 Shield Therapeutics 0.61%
Grant of Share Options
10Jul17 16:16 AV. LSE,STX LSE 1.25%
Holding(s) in Company
06Jul17 07:00 Shield Therapeutics 0.61%
Feraccru licence agreement for Switzerland
05Jul17 12:38 Shield Therapeutics 0.61%
Holding(s) in Company
03Jul17 12:34 Shield Therapeutics 0.61%
Warrant Exercise and Expiry
28Jun17 10:37 Shield Therapeutics 0.61%
Holding(s) in Company
28Jun17 08:00 Shield Therapeutics 0.61%
Admission of New Ordinary Shares
15Jun17 13:59 Shield Therapeutics 0.61%
Results of Fundraise
15Jun17 07:00 Shield Therapeutics 0.61%
Proposed Fundraise
13Jun17 14:40 Shield Therapeutics 0.61%
Result of AGM
26May17 07:00 Shield Therapeutics 0.61%
Appointment of Joint Broker
28Apr17 07:00 Shield Therapeutics 0.61%
Annual Report, Accounts and AGM Notification
04Apr17 07:00 Shield Therapeutics 0.61%
Appointment of Chief Financial Officer
04Apr17 07:00 Shield Therapeutics 0.61%
Preliminary Results for the Year Ended 31 Dec 2016
13Mar17 07:00 Shield Therapeutics 0.61%
Notice of Results